/Tag: Rare Diseases
4 02, 2020

WSCS 2020 Wrap Up: Biorasi joins the global dialogue for regenerative medicine

By |2020-02-04T18:05:29+00:00February 4th, 2020|Tags: , , , , , |

When stem cell industry innovators from across the globe congregated in Miami at the end of January 2020 to discuss the current state and future expectations of the regenerative medicine industry, Biorasi had more than one reason to be excited about the event. Read the full article for highlights >>

30 10, 2019

NORD Breakthrough Summit: 3 Key Takeaways

By |2019-11-18T16:39:51+00:00October 30th, 2019|Tags: , , , |

A team from Biorasi joined more than 900 leaders from the FDA, NIH and the pharma and bio-pharma industries for the National Organization for Rare Disorders (NORD) & Orphan Products Breakthrough Summit. Throughout two packed days of keynotes, breakout sessions and panel discussions, we gained valuable insight into the most urgent rare disease topics. Read about the a few takeaways from the event in this article.

4 09, 2019

Acute Kidney Injury (AKI): Management and Outcome

By |2020-02-03T11:46:33+00:00September 4th, 2019|Tags: , , , |

In my previous article, I explained the types, causes and symptoms of Acute Kidney Injury (AKI). Here, I’ll share how physicians treat and manage AKI, as well as what to expect. CRRT or intermittent hemodialysis? To treat AKI, nephrologists primarily use renal replacement therapy (RRT), which includes intermittent hemodialysis, peritoneal hemodialysis, various forms of CRRT, and “hybrid” therapies such as prolonged intermittent renal replacement therapy (PIRRT) or sustained low-efficiency hemodialysis (SLED). A few clinical trials are taking a look at CRRT and intermittent hemodialysis under different conditions.

22 08, 2019

Rare Disease: 5 Steps to Successful Program Development

By |2020-04-07T12:24:20+00:00August 22nd, 2019|Tags: , , |

There may be as many as 7,000 rare diseases. Support from FDA, EMA and other regulatory agencies, combined with technological and scientific advances, have made it more feasible for pharmaceutical companies to give dedicated attention to orphan drug development. In doing so, they're developing medications for rare diseases that often have no cure and no available treatment. To ensure novel therapies advance from the lab to regulatory approval, a blockbuster-drug approach won't work. Managing rare disease studies to completion requires innovative thinking in nearly every phase of program development.

23 07, 2019

Orphan Drugs and Rare Diseases Global Congress 2019 Americas

By |2019-07-24T16:37:48+00:00July 23rd, 2019|Tags: |

Biorasi will be at the 2019 Orphan Drugs and Rare Diseases 2019 Americas – West Coast from July 23rd - 24th 2019 in San Francisco, CA, USA. We would like to extend a cordial invitation to all of our partners, sponsors, and friends to come talk to us!. We will be showcasing how Biorasi is a new kind of CRO in how we manage clinical trials, as well as providing information on our Rare Disease Study expertise.

17 07, 2019

FSGS: A rare kidney disease without targeted therapies

By |2019-10-31T12:23:52+00:00July 17th, 2019|Tags: , |

Researchers are studying a few new and existing drugs to treat FSGS. FSGS needs a novel medication that regulates both high body fats and inflammasome inhibition via upstream innate immune system to block intracellular initiation of inflammatory cascade and extra cellular inflammation. Over the past five years, nearly 30% of Biorasi-initiated or ongoing studies involved chronic kidney disease. Our experience allows us to develop successful nephrology clinical trials.

11 06, 2019

Rare Disease Spotlight: C3 Glomerulopathy

By |2019-09-03T16:51:05+00:00June 11th, 2019|Tags: |

C3 glomerulopathy (C3G), a rare kidney disease, affects only two or three people out of every one million. That’s only a couple people out of the entire population of San Jose, California or Austin, Texas. Although C3G only affects a select few, without treatment it can lead to severe kidney damage and failure, necessitating expensive dialysis or transplant. To date, there is no specific, effective therapy. As a CRO that understands the challenges involved in researching rare disease treatments, we’re here to help drug developers deliver the most effective clinical trials possible—on time and on budget. Speak with one of our rare disease experts today to find out how we can help you develop your next rare disease program.

Download our Precision Medicine Checklist

Complete the form below to receive a link to download this checklist
close-link

Schedule a call with one of our experts today

Let us know how we can help. Our team would like to connect with you!
close-link

Start your FREE Trial Rescue Assessment!

Complete the form below and we will provide our free trial rescue assessment.
close-link

Download our Patient-Centric Trials White Paper

Complete the form below to receive a link to download this white paper
close-link

Download our Data Science White Paper

Complete the form below to receive a link to download this white paper
close-link

Schedule a TALOS™ Control Center Demo

Complete the form below to schedule a demo with our program development team
close-link

Download our Rare Disease Checklist

Complete the form below to receive a link to download this checklist
close-link

Download our Dermatology White Paper

Complete the form below to receive a link to download this white paper
close-link

Get Access to "Making Most of Trial Data" Webinar

Complete the form below to receive a link to access this webinar
close-link

Download our Precision Oncology White Paper

Complete the form below to receive a link to download this whitepaper
close-link

Download Rare Disease Program Development White Paper

Complete the form below to receive a link to download this whitepaper
close-link

Get access to "Strategies for Successful Digital Therapeutics Clinical Trials" Webinar

Complete the form below to receive a link to access this on-demand webinar
close-link

Schedule a call with one of our experts today

Let us know how we can help. Our team would like to connect with you!
close-link

Schedule a call with one of our experts today

Let us know how we can help. Our team would like to connect with you!
close-link

Download our Trial Rescue White Paper

Complete the form below to receive a link to download this white paper
close-link

Download our Advance Analytics Monitoring White Paper

Complete the form below to receive a link to download this white paper
close-link

Download our Nephrology Clinical Trials White Paper

Complete the form below to receive a link to download this resource
close-link

Download our Regulatory Clinical Trial White Paper

Complete the form below to receive a link to download this white paper
close-link

Download ANDA Program Optimization WP

Complete the form below to receive a link to download this white paper
close-link

Get Access to "Solving at Risk Trials" Webinar

Complete the form below to receive a link to access this on-demand webinar
close-link

Watch "Decentralized Clinical Trials" Webinar

Complete the form below to receive a link to access this on-demand webinar
close-link
Biorasi uses cookies for analytics to improve your experience on this website. By continuing to browse this site, you agree to this use. Please review our Privacy Policy for more information. Ok